Leading radiosurgery systems maker
) recently disclosed that the Instituto Neurologico de Colombia
("INDEC") of South America, for the first time, has started
treating its patients with the CyberKnife Radiosurgery System in
May 2012. The INDEC is the largest clinical neuroscience center in
Latin America, which houses some of the best technologies and
physicians in the region.
The Columbia-based INDEC is the pioneer institute in South
America to be using this advanced robotic radiosurgery device to
cure both cancerous as well as non-cancerous tumors in the body.
The first patient treated with the CyberKnife at the INDEC had a
complex spinal tumor which could not be treated with any other
medical device available at the center.
Since then, the CyberKnife is being used to treat all kinds of
tumors (including both intracranial and extracranial) in a safe
non-invasive manner that were earlier rendered untreatable in the
Accuray is a renowned radiation oncology company with a rich
history of rapid innovation and cutting-edge technologies.
CyberKnife and the TomoTherapy Systems are two of its flagship
products. With the market size for the global radiation therapy
market expected to reach $3.6 billion by 2018 (as per GlobalData),
Accuray is focussing on investing in emerging markets to expand its
The CyberKnife System boasts of a technology that differentiates
it from traditional treatments. CyberKnife, a non-invasive
alternative to conventional surgery, is the first and only
commercially available intelligent robotic radiosurgery system
designed to treat solid tumors anywhere in the body.
CyberKnife System reduces the overall time and resources
required for surgery, when compared to traditional methods. This
leads to an increase in the volume of procedures performed and
lower per procedure costs for the hospital.
Accuray continues to enjoy healthy demand for CyberKnife
radiosurgery system as evidenced by sustained growth in the number
of patients receiving treatment with the device. Moreover, the
acquisition of rival TomoTherapy has bolstered the company's
foothold in the radiation oncology space.
However, Accuray remains susceptible to reimbursement
uncertainties and faces stiff challenges from competitive product
). We currently have a Neutral recommendation on Accuray. The stock
currently retains a Zacks #2 Rank, which translates into a
short-term Buy rating.
ACCURAY INC (ARAY): Free Stock Analysis Report
VARIAN MEDICAL (VAR): Free Stock Analysis
To read this article on Zacks.com click here.